Movement Disorders
Hemifacial spasm
Oct. 24, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Neuro-ophthalmology of movement disorders …
- Updated 06.19.2024
- Released 02.10.2012
- Expires For CME 06.19.2027
Neuro-ophthalmology of movement disorders
Introduction
Overview
In this article, the author reviews neuro-ophthalmologic manifestations of the most common movement disorders, including Parkinson disease and atypical parkinsonism, dystonia, Huntington disease, Tourette syndrome, cerebellar disorders, and psychogenic and pediatric movement disorders. This article discusses phenomenology, pathophysiology, and management of the ocular symptoms that can be encountered in patients with movement disorders.
Key points
|
• Ophthalmologic symptoms are common in patients with movement disorders. | |
|
• Ophthalmologic symptoms are often underestimated but may be troublesome for the patients and adversely impact their quality of life. | |
|
• Pathophysiology of some neuro-ophthalmologic manifestations in movement disorders is complex and poorly understood. | |
|
• Recognition and treatment of the ocular symptoms are important when managing patients with a variety of movement disorders. |
Clinical manifestations
Many movement disorders and most neurodegenerative diseases are associated with a variety of visual and ocular motor impairments that may be troublesome for the patients and adversely impact their quality of life (137; 92; 133). These ophthalmologic symptoms may arise from problems with visual processing, impaired subcortical and cortical control of eye motility, and other still poorly understood mechanisms. The neuro-ophthalmologic features of some of the most common movement disorders are discussed in this article and summarized in Table 1.
Ophthalmologic signs of disorders with parkinsonism include the following:
|
• Patients with Parkinson disease have a variety of sensory and motor ocular symptoms indicating dysfunction at multiple anatomical levels, from ocular structures to cortical centers. | |
|
• Ophthalmologic symptoms interfere with daily activities in two-thirds of patients with Parkinson disease. | |
|
• Some ophthalmologic findings in Parkinson disease correlate with disease progression and might potentially serve as disease biomarkers. | |
|
• Ocular motor deficit is a cardinal feature of progressive supranuclear palsy. |
Parkinson disease. Ophthalmologic sensory and motor symptoms in patients with Parkinson disease can result from dysfunction at several anatomic levels, including ocular and orbital structures, subcortical pathways, and cortical centers involved in regulation of ocular motility and visual processing. In an observational study of 848 patients with Parkinson disease and 250 healthy controls, one or more ophthalmologic symptoms were reported by 82% of patients and 42% of healthy adults (20). Ophthalmologic symptoms interfered with daily activity in 68% of patients. Subjective dry eye symptoms were reported in 61% of patients with Parkinson disease (98). Other common ocular complaints reported by about two thirds of patients with Parkinson disease are photophobia, tearing, eye pain, or gritty eye sensation suggestive of ocular surface irritation (17; 20). Reduced blink rate can contribute to precorneal tear film dysfunction and worsen eye discomfort in patients with Parkinson disease. This ocular surface irritation on a background of primary basal ganglia dysfunction has been implicated in the development of peripherally induced blepharospasm (64; 56; 71). Blepharospasm with or without apraxia of eyelid opening, characterized by difficulties opening the lids after voluntary closure, is more common in advanced idiopathic Parkinson disease or atypical parkinsonism with progressive supranuclear palsy, leading the group of parkinsonian disorders associated with prominent eyelid motility dysfunction (17; 139; 110). In patients with Parkinson disease and other parkinsonian syndromes, reduced blink rate often co-exists with glabellar reflex, or Myerson sign, and is characterized by nonsuppression of blinking with repetitive tapping of the glabella. This reflex is a relatively sensitive sign of Parkinson disease and atypical parkinsonism, but it lacks specificity to differentiate between particular parkinsonian disorders (23). Blink rate can be influenced by the corneal sub-basal nerve density, and the latter was found to be markedly reduced in 15 patients with Parkinson disease as compared to healthy controls (95). Previous studies have reported that the spontaneous eyeblink rate correlated with the dopamine levels in the brain and plasma levodopa levels; therefore, it might serve as a potential biomarker of the dopaminergic brain function and motor fluctuations in patients with Parkinson disease (68).
Search for potential biomarkers of Parkinson disease in tear chemical profile revealed significantly elevated levels of oligomeric α-Synuclein, CCL2 (a secreted chemokine induced by TNF- α), and lactoferrin in reflex tears (tears in response to stimulation of sensory nerves of the ocular surface) in patients with Parkinson disease relative to healthy controls (59; 115). Other changes in tear biochemistry found in search for potential biomarkers of Parkinson disease include decreased levels of total alpha-synuclein, increased levels of norepinephrine, dopamine, and alpha-2-macroglobulin compared to tears from healthy controls (80; 25). Proteins involved in immune response, lipid metabolism, oxidative stress, collagen degradation, protein synthesis, lipid transport were found to be deregulated in tears of patients with Parkinson disease (80). A study of proteome profiles of 24 patients with idiopathic Parkinson disease, three carriers of E46K mutation in alpha-synuclein gene (SNCA), and 27 healthy controls identified six deregulated proteins in patients with Parkinson disease (01). These proteins were associated with alterations in lysosomal autophagy, apoptosis, retrograde axonal transport, and demyelination. Three of those proteins showed good capability to differentiate patients with Parkinson disease from healthy controls – cathepsin D, acid ceramidase, and cytoplasmic dynein 1.
Impaired eye motility is another common ophthalmologic finding in patients with Parkinson disease (108; 06). This group of symptoms includes convergence insufficiency, abnormal saccades (rapid eye movements that shift gaze from one location to another), impaired smooth pursuit, upgaze limitation, and square-wave jerks (inappropriate saccades that take the eye off the target, followed by inter-saccadic interval, and another corrective saccade that brings the eye back to the target). In patients with Parkinson disease, saccades are usually hypometric. Saccadic latency increases and velocity decreases as disease progresses. Although reflexive, visually-guided saccades (prosaccades) are usually preserved in early stages of disease, voluntary saccades represented by anti-saccades (saccades in the opposite direction to a stimulus) and memory-guided saccades (saccades for a remembered target that has subsequently disappeared) are commonly impaired in early Parkinson disease (22; 123). Prosaccadic latency is significantly affected (prolonged) by dopaminergic medication. On the contrary, antisaccadic latency is affected largely by the disease state with no medication effect (90). Antisaccade task is sensitive to detecting impairment of inhibitory and impulse control; however, it is not specific to Parkinson disease and can occur in other neurodegenerative disorders. Impaired smooth pursuit is observed in more advanced Parkinson disease and characterized by deficit in smooth pursuit gain, intrusion of catch-up saccades, decreased peak velocity, and progressive displacement reduction with repetitive movements similar to that seen with other motor tasks in Parkinson disease (84). The latter phenomena could be potentially explained by easy fatigability in Parkinson disease rather than direct disruption of ocular smooth pursuit pathways as they are not directly connected to the basal ganglia (79). Visual exploration strategies that consist of alternating runs of saccades and gaze fixations were found to be impaired in patients with Parkinson disease versus healthy controls, and more affected in Parkinson disease patients with cognitive impairment versus Parkinson disease with normal cognitive function (09). Convergence insufficiency (inability to maintain binocular eye alignment on an object as it approaches from distance to near) is another common neuro-ophthalmologic feature of Parkinson disease. Decreased convergence amplitude (measured by placing increasing base out prism over one eye until a patient develops diplopia due to inability to fuse near target) can be accompanied by normal near point of convergence in early Parkinson disease (17) or more remote near point later in the course of the disease (02). Convergence insufficiency in association with presbyopia can be worsened by base-out effect (prism rotation towards the ear) from bifocal lenses often prescribed to older people. On the other hand, monocular vision using a simple eye-patch over one eye may actually facilitate reading in patients with Parkinson disease with marked convergence insufficiency. Patients with Parkinson disease also frequently have mild restriction of upgaze as opposed to limitation of downward gaze in another parkinsonian disorder, progressive supranuclear palsy. Deficits in ocular fixation, manifesting as pervasive oscillatory eye movements while attempting to fixate on a still object, is another characteristic ocular phenomenon in Parkinson disease, named ocular tremor, with no difference between medicated versus nonmedicated patients (50). The controversy remains around ocular tremor being a presentation of Parkinson disease tremor similar to limb tremor and often having the same frequency versus just vestibulo-ocular reflex induced by head oscillations transmitted from a tremulous limb (50; 37; 78; 51).
Visual perception is also impaired in Parkinson disease affecting visual acuity, color discrimination, contrast sensitivity, and perception of motion (75; 107; 33; 96; 127; 08; 100; 18; 12). The Survey of Health, Ageing, and Retirement in Europe (SHARE) study of 115,240 individuals 50 years of age and older conducted in 27 countries reported increased odds of impaired overall (odds ratio 2.67), distance (odds ratio 2.55), and near (odds ratio 2.07) eyesight in patients with Parkinson disease compared to nondiseased individuals (58). Electroretinography and optical coherence tomography, coupled with pathological findings of thinning of the retinal nerve fiber layer, provide evidence for retinal foveal deficit in Parkinson disease (18). Some studies have suggested retinal thinning in patients with Parkinson disease, partly due to dopaminergic neuronal loss (19). Retinal nerve fiber layer thinning may be associated with visual hallucinations and risk of dementia (83; 87; 131). Impaired color discrimination was found mainly along red-green axis in the contrast to aging-dependent color vision impairment affecting mainly blue-yellow axis or retinal disease where all color axes are affected (08; 100). Contrast sensitivity and color discrimination impairment often worsens with progression of Parkinson disease but may improve with levodopa (65; 24). Decreased sensory visual function in Parkinson disease can be a consequence of retinal and postretinal dysfunction. Primary deficiency of retinal dopaminergic circuits with reduced dopamine level in retina was found in patients with Parkinson disease (99; 61). Previous studies reported thinning of inner retina even in early Parkinson disease, with alpha-synuclein accumulation discovered in the postmortem eyes of some but not all patients with Parkinson disease (31; 55; 19; 27). Degree of foveal thinning and retinal nerve fiber atrophy were correlated with Parkinson disease duration and severity in studies (118). Thinning of the retinal nerve fiber layer was found to be more significant in the temporal and inferior quadrants of the retina in patients with Parkinson disease compared to healthy controls, especially in the eye contralateral to the side of the body most affected by Parkinson disease (82; 141). Similar pattern of retinal pathology with predominant temporal fibers atrophy is observed in axonal optic neuropathies associated with mitochondrial disorders involving complex I defect, such as Leber hereditary optic neuropathy. This observation might support the hypothesis of mitochondrial dysfunction in the pathogenesis of Parkinson disease (82). It is not well known if retinopathy alone or its combination with affected subcortical visual pathways and cortical visual processing centers can be implicated in sensory visual dysfunction in Parkinson disease (08). Changes in choroid layer thickness and choriocapillaris vascular flow density in the eye of patients with Parkinson disease were identified with the use of optical coherence tomography (34; 140). Some studies reported decrease of the choroid thickness in Parkinson disease and attributed it to blood flow irregularities and atrophy (39). On the contrary, other studies using a different method of measuring choroid thickness found thickened macular and peripapillary choroid in Parkinson eyes (119). The authors suggested the alterations in perivascular connective tissue density and not hypoperfusion alone to be the mechanisms behind the changes in the choroid layer in Parkinson disease. The study evaluating macular thickness and peripapillary retinal nerve fiber layer in 28 healthy controls, 48 patients with Parkinson disease, 18 with progressive supranuclear palsy, and 38 with multiple system atrophy found different patterns of retinal changes in all groups, thus suggesting that optical coherence tomography could be a biomarker for differential diagnosis of parkinsonian disorders (91). Macular thickness and volume were markedly thinner in multiple system atrophy than in Parkinson disease, whereas patients with progressive supranuclear palsy had increased retinal nerve fiber thickness in temporal sector compared to other patients and healthy controls. A study of 156 patients with Parkinson disease followed for 6 years reported that subjects with slower rate of progression of retinal degeneration demonstrated more rapid cognitive decline (97). Those subjects were of older age, had longer disease duration, and had higher cognitive and motor disease stage scores at baseline.
Visual hallucinations are common among patients with Parkinson disease and could be at least partially related to impaired visual processing (43; 131). Functional brain imaging in Parkinson disease patients with visual hallucinations identified global loss of connectivity affecting attention and perception (62). The majority of hallucinations are minor, such as illusions, sensation of presence, or sideways passage of a live object. Formed visual hallucinations are less frequent. Risk factors for hallucinations in Parkinson disease are advanced disease, significant cognitive decline, ocular disorders, and sleep-wake cycle disturbance (43). Although use of dopaminergic and anticholinergic medications without other contributors was thought not to be an important risk factor for hallucinations (43; 94), anti-Parkinson disease medications, particularly dopamine agonists, levodopa, and anticholinergic medications, clearly play an important role in visual hallucinations as reduction in dosage or discontinuation leads to improvement or resolution of this symptom, and this strategy is recommended in management. Visual hallucinations early in the course of the disease might suggest evolution into dementia with Lewy bodies (43).
Several case reports described corneal edema as a side effect of amantadine, which is often used for treatment of motor symptoms of Parkinson disease (45; 93). Relative risk of corneal edema was estimated at 1.7 among the patients on amantadine, and it was usually observed within the first year of amantadine use. The exact mechanism of corneal edema remains unclear. Because only a small number on patients treated with amantadine develop corneal edema, it was suggested that the variable distribution of the dopamine receptors in the endothelial cells of the cornea might explain increased sensitivity to dopamine in some but not all patients. Few cases of reversible corneal edema linked to the use of ropinirole were also reported (93).
Recognition and treatment of the ophthalmologic symptoms in patients with Parkinson disease can significantly improve their quality of life. Inadequate corneal lubrication can be improved with the use of artificial tears. In severe cases of dry eyes, punctal occlusion might be beneficial. Botulinum toxin injections are used in the treatment of blepharospasm with or without apraxia of eyelid opening. Visual perception in patients with Parkinson disease with abnormal contrast sensitivity and color discrimination can be improved by the use of ample ambient light while reading (17). Reading glasses with base-in rather than base-out lenses should be prescribed to patients with convergence insufficiency. If comfortable binocular vision cannot be achieved with appropriate lenses, patients can use monocular occlusion while reading or using a computer. Visual hallucinations may require modification of Parkinson disease medications. Atypical neuroleptics or pimavanserin, a selective serotonin 5-HT2A inverse agonist, might be prescribed to the patients with Parkinson disease who have persistent hallucinations (32; 30).
Progressive supranuclear palsy. Impaired eye motility is a cardinal feature of progressive supranuclear palsy that helps to differentiate this disorder from similar neurodegenerative diseases with parkinsonism. Slowing of vertical, particularly downward, saccades even in the presence of full range of vertical gaze, best elicited by moving an optokinetic tape in an upward direction, is one of the earliest neuro-ophthalmological signs of progressive supranuclear palsy. Slowing of horizontal saccades, hypometric saccades, impaired antisaccades and smooth pursuit, abnormal downward optokinetic nystagmus with impaired slow phase response, and slow quick phase combined with square-wave jerks are also among the earliest ocular motor features of progressive supranuclear palsy, often preceding the development of characteristic supranuclear gaze palsy or other motor signs (128; 113; 47; 60; 11; 54). Square-wave jerks are much more prevalent in progressive supranuclear palsy as compared to healthy controls and patients with Parkinson disease. The volumes of the midbrain measured with Voxel-based morphometry MRI were not correlated with the square-wave jerk rate (04). Instead, associations were found for atrophy in the superior, middle, and inferior temporal gyri. The findings indicate that supratentorial cortical structures located mainly in the temporal lobe are deeply involved in the generation of abnormally high square-wave jerk rates in patients with progressive supranuclear palsy. With progression of the disease, vertical eye movement limitation occurs with downgaze palsy developing before upgaze restriction, followed by limitation of lateral eye movements, sometimes preceded by internuclear ophthalmoplegia, and eventually progressing to complete ophthalmoplegia. Another characteristic sign of progressive supranuclear palsy is the "round the houses" sign (109; 105). The patient exhibiting this sign is unable to make pure vertical saccades along a straight line in the midline; instead, his eye makes a lateral arc, which creates a curve course of oblique saccades.
Ability to overcome ophthalmoparesis with an oculocephalic maneuver is lost in the late stages of progressive supranuclear palsy (nuclear ophthalmoplegia), indicating involvement of brainstem nuclei in the pathological process (67). Degeneration of the subcortical pathways and cortical centers of eye motility are implicated in the prominent ocular motor symptoms of progressive supranuclear palsy (57; 135). Although ophthalmoparesis is the clinical hallmark of progressive supranuclear palsy, pathologically documented cases of progressive supranuclear palsy without ophthalmoparesis have been reported (28). On the other hand, it is important to remember that supranuclear ophthalmoparesis can occur in other disorders, such as corticobasal degeneration, dementia with Lewy bodies, postencephalitic parkinsonism, Wernicke encephalopathy, Whipple disease, stiff-person syndrome, neuroacanthocytosis, progressive external ophthalmoplegia, hydrocephalus, Kufor-Rakeb syndrome, and other neurologic disorders.
Abnormal eyelid motility in progressive supranuclear palsy, including decreased blink rate, eyelid retraction, blepharospasm and apraxia of eyelid opening and closure, can be present already in early stages of the disease (46; 53). Apraxia of eyelid movements is often attributed to supranuclear inhibition of levator palpebrae muscle (85), loss of reciprocal relationship between levator palpebrae and pretarsal portion of the orbicularis oculi muscles (106), or eyelid freezing similar to sudden freezing of the other movements in parkinsonian disorders (69). Eyelid reflexes are also impaired, including acoustic blink reflex (a brief eye closure in response to a sudden sound) (49). Abnormal eyelid and ocular motility combined with “worried” or “astonished” facial expression, partly due to contraction of the procerus and possibly corrugator muscles (so called “procerus sign”), create a characteristic facial appearance of a patient with progressive supranuclear palsy that can be distinguished from other parkinsonian disorders (116).
Other less known but not uncommon ophthalmologic features of progressive supranuclear palsy are decreased pupillary diameter in the dark (120), involuntary persistence of ocular fixation (absent suppression of ocular fixation to allow gaze shifts), and difficult suppression of the vestibule-ocular reflex (111). Patients with progressive supranuclear palsy might have vertical jerky eye oscillations during oculographic testing that might be interpreted as “downbeat nystagmus.” However, Ticku and colleagues have observed that those oscillations were phase-locked and frequency-matched with subtle head jerks and that they could be eliminated by adequate head stabilization (126). Therefore, such vertical eye oscillations were interpreted as “pseudonystagmus” representing vestibulo-ocular reflex. Thinning of peripapillary retinal nerve fiber layer and macula were reported in 19 patients with progressive supranuclear palsy compared to healthy controls (26).
Other parkinsonian disorders. In addition to Parkinson disease and progressive supranuclear palsy, blepharospasm may be a disabling symptom in patients with multiple system atrophy (17; 76). Dry eyes, conjugate eye movement abnormalities, and ocular misalignment are the most common findings in patients with multiple system atrophy (48). The disease is also often associated with a variety of ocular motor abnormalities, including spontaneous and gaze-evoked nystagmus, square wave jerks, slow and hypometric saccades, diminished vestibular-ocular reflex suppression, internuclear ophthalmoparesis, reduced vestibulo-ocular reflex suppression, and impaired vertical gaze (05; 40). Gorges and colleagues studied smooth pursuit and visually guided reactive saccades compared to the microstructural alterations on the brain diffusion tensor imaging in patients with Parkinson disease, progressive supranuclear palsy, and multiple system atrophy (52). Smooth pursuit was impaired in patients with multiple system atrophy with “catch-up” saccades, resulting in significantly reduced pursuit gain. The shape of saccadic pursuit was correlated with alterations on diffusion tensor imaging in the middle cerebral peduncle. Peak eye velocity was markedly reduced in patients with progressive supranuclear palsy and correlated significantly with microstructural impairment in the midbrain.
In corticobasal degeneration, horizontal saccades commonly have prolonged latency correlating with “apraxia score” but normal speed of saccadic eye movements (128). Vertical saccades are usually preserved or only minimally impaired on upward gaze.
One of the most prominent features of dementia with Lewy bodies is the presence of visual hallucinations early in the course of the disease. Patho-anatomical studies identified nonspecific neurodegenerative changes without alpha-synuclein inclusions in postmortem retinas of patients with dementia with Lewy bodies, but Lewy bodies were identified in substantia nigra and neocortex (31). Furthermore, amplitude, velocity, and latency of saccades are typically impaired in dementia with Lewy bodies (77).
Ophthalmologic signs of hyperkinetic movement disorders include the following:
|
• Saccades impairment is an early ophthalmologic sign of Huntington disease and can serve as the biomarker of disease progression. | |
|
• Ocular motor signs ranging from nystagmus and impaired saccades to ophthalmoplegia are common ophthalmologic findings in diseases with cerebellar pathway dysfunction independent of etiology. | |
|
• Ophthalmologic findings in Wernicke encephalopathy are reversible and improve dramatically with thiamine replacement treatment. |
Huntington disease. Impaired saccadic eye movements are among the earliest signs of Huntington disease and are characterized by increased saccade latency with increased variability of saccade latency, slowing of vertical and horizontal saccades, and difficulty suppressing reflexive saccades. Abnormal saccadic latency in Huntington disease demonstrates more systematic and steady worsening year-to-year than progression of other motor abnormalities, thus, highlighting the importance of this ocular sign in tracking disease progression (07). Voluntary saccades, including antisaccades and memory-guided saccades, were shown to be more consistently affected early in the course of disease than reflexive saccades; but both reflexive and voluntary eye motor control in patients with Huntington disease has been shown to decrease with increased disease severity, suggesting that simple tasks, such as prosaccades and antisaccades, can serve as quantitative biomarkers of disease progression in Huntington disease (103).
Increased saccadic latency and error rates can be observed in the premanifest stage of Huntington disease in proportion to the predicted age of the disease onset (63). Correlation was also found between latency of vertical antisaccades and degree of atrophy in the left superior frontal gyrus, left inferior parietal lobule, and bilateral caudate nuclei (117). Coppen and colleagues reported correlation between oculomotor dysfunction and cortical volume loss on brain MRI, especially in occipital regions, whereas chorea was mainly associated with subcortical volume loss (29). Other ocular motor findings in Huntington disease include increased blink rate and impaired smooth pursuit, but despite loss of balance, the vestibulo-ocular reflex appears to be preserved. Blepharospasm and apraxia of eyelid opening and closing are rare ocular signs of Huntington disease.
Significant reduction in macular retinal thickness and inferior peripapillary retinal nerve fiber layer thickness was found in Huntington disease patients compared to healthy controls with 25 subjects in each study arm (03). Another study of 41 Huntington patients and 41 healthy controls reported diffuse retinal changes in retinal nerve fiber layer and macula in the diseased group but concluded that the changes were too small and not suitable to be considered as biomarkers of the disease (36).
Dystonia and other facial spasms. Blepharospasm is a type of focal dystonia affecting eyelids and often can be a part of cranial-cervical dystonia. Many patients with blepharospasm present with the complaints suggestive of ocular surface irritation, such as dry eye, photophobia, or sensation of foreign object in the eye (56; 102). Before the development of sustained eyelid spasms that are characteristic features of blepharospasm, about one third of the patients recall having excessive blinking. As the disorder progresses, the patients develop clonic and later tonic (sustained) contractions of orbicularis oculi muscles causing forceful closure of the eyelids. This should be differentiated from ptosis caused by weakness of the levator palpebrae. Blepharospasm is usually an idiopathic disorder, a form of primary focal dystonia; however, it can occur as secondary dystonia in the setting of tardive dystonia, structural brain lesions (such as stroke or multiple sclerosis), or as a symptom of some neurodegenerative disorders (eg, atypical parkinsonism, Huntington disease). Blepharospasm may be associated with apraxia of eyelid opening or closure, particularly in patients with atypical parkinsonism.
In primary blepharospasm, apraxia of eyelid opening was reported in 4% of patients (104). Botulinum toxin injections are very effective in the treatment of blepharospasm, but apraxia of eyelid opening is much more difficult to treat with botulinum toxin unless the latter is triggered by the blepharospasm (70; 72). Transient improvement of blepharospasm was observed in seven patients treated with apraclonidine, an alpha-2 adrenergic receptor agonist that causes contraction of superior tarsal (Müller) muscle resulting in improvement of blepharospasm-related eyelid closure (129).
Oculogyric crisis is a type of focal dystonia characterized by sustained contractures of ocular muscles, resulting in conjugate tonic ocular deviation usually up or to one side. Oculogyria was a prominent ophthalmologic sign of encephalitis lethargica and subsequent postencephalitic parkinsonism, a disorder that is rarely seen in present days (130). Today, oculogyric crisis is usually indicative of drug-induced acute and tardive dystonic reaction as a complication of dopamine-blocking medication use (44). This symptom can also be observed in a group of inherited disorders of monoamine metabolism, such as aromatic amino acid decarboxylase deficiency, tyrosine hydroxylase deficiency, and pterin metabolism defect (81; 136). Because inherited metabolic disorders often manifest in childhood, it is important to differentiate oculogyric crisis from a relatively benign childhood condition called paroxysmal tonic upgaze of infancy (88). Infants present with paroxysmal conjugate deviation of the eyes upward associated with neck flexion, downbeat saccades on attempted downgaze, mild ataxia or otherwise normal neurologic examination and ancillary tests, and ultimate resolution of the symptoms without residual deficit or with minor oculomotor symptoms and borderline cognitive disability.
Hemifacial spasm is not classified as focal dystonia but rather a peripherally induced movement disorder involving facial muscles, including periorbital muscles and eyelids, and often causing eye closure that can resemble blepharospasm (138). In contrast to blepharospasm, hemifacial spasm is almost always unilateral. Another feature that can help to distinguish these two disorders from each other is ipsilateral eyebrow elevation by frontalis contraction in hemifacial spasm, so-called “other Babinski sign” (124), as opposed to depression of the eyebrows in blepharospasm due to contraction of the procerus, corrugator, and orbicularis oculi muscles.
Hemifacial spasm is most frequently caused by facial nerve compression by a blood vessel at the exit of the nerve root, but it can be encountered in patients with demyelinating CNS disease, structural lesions in the middle, or posterior cranial fossa. Botulinum toxin injections are considered the treatment of choice for hemifacial spasm, although surgical vascular decompression of the facial nerve is still used in some cases.
Tourette syndrome. Motor tics in Tourette syndrome often involve ocular or eyelid movements (73). Excessive blinking is one of the most common simple clonic tics. Oculogyric deviations seen in 28% of patients with Huntington disease and blepharospasm (15% of patients) are the examples of simple dystonic tics (74).
Patients with Tourette syndrome also demonstrate higher rate of antisaccades errors than healthy controls (41). Although dopamine-blocking or dopamine-depleting drugs are often used in the management of tics, botulinum toxin injections can provide additional benefit for blinking tics and blepharospasm associated with Tourette syndrome.
Movement disorders with ataxia. Movement disorders with ataxia as a main component of clinical presentation include multiple types of hereditary spinocerebellar atrophy, ataxia-telangiectasia syndrome, episodic ataxias, multiple system atrophy, alcohol-related cerebellar degeneration, and other disorders (16). Gaze-evoked and spontaneous nystagmus, ocular dysmetria with hypermetric saccades (overshoot of eye movements), square-wave jerks, and impaired smooth pursuit with saccadic intrusions are common ophthalmologic signs of heterogeneous diseases with cerebellar pathway dysfunction independent of etiology.
Some ocular symptoms are observed mostly or exclusively in certain types of spinocerebellar ataxias (101). Slow saccades occur in spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, and spinocerebellar ataxia type 7. Spinocerebellar ataxia type 3 can be associated with supranuclear ophthalmoparesis, rebound nystagmus, lid retraction with bulging eyes, and decreased blink rate. Retinal changes with thinning of peripapillary retinal nerve fiber layer, ganglion cell layer, and inner plexiform layer were found in patients with spinocerebellar ataxia type 3 compared to healthy controls (112). Retinal layers thickness negatively correlated with ataxia severity rating scales. Downbeat positional nystagmus and rebound nystagmus are often seen in spinocerebellar ataxia type 6. Spinocerebellar ataxia type 7 is the only spinocerebellar atrophy syndrome with prominent visual disturbances, including retinal degeneration and pigmentary retinopathy with optic atrophy leading to blindness. Visual disturbance might precede other neurologic symptoms in spinocerebellar ataxia type 7 (101). Progressive ophthalmoplegia is another characteristic feature of spinocerebellar ataxia type 7. Retinal nerve fiber layer thinning and optic nerve atrophy were documented in patients with spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, and spinocerebellar ataxia type 3 (101).
Ataxia-telangiectasia is an autosomal-recessive disorder with early ocular signs, such as conjunctival telangiectasia and oculomotor apraxia, manifested by loss of volitional saccades so that the patients thrust their heads in the direction of interest to bring the eyes into alignment with the object of interest (114). Other neuro-ophthalmological signs associated with ataxia-telangiectasia include impaired fixation, accommodation deficiency, impaired smooth pursuit, hypometric saccades, nystagmus, increased blink rate, and photophobia.
Episodic ataxia type 1 is a channelopathy involving potassium channels often presenting with periorbital myokymia, which persists even between the ataxia attacks (132). Episodic ataxia type 2 is a calcium channelopathy disorder with characteristic downbeat nystagmus along with bouts of ataxia often with diplopia.
Wernicke encephalopathy is a neurologic disorder secondary to thiamine deficiency that manifests as a triad of altered mental status, ataxia, and ocular motor abnormalities; however, many patients present with an incomplete clinical triad. Nystagmus is the most common ophthalmologic presentation of Wernicke encephalopathy. It ranges from gaze-evoked, nonsustained horizontal nystagmus in early stages of the disease to sustained nystagmus with gaze-holding failure in later stages (66). Primary gaze upbeat nystagmus is observed in Wernicke encephalopathy, and it sometimes switches to permanent downbeat nystagmus that is thought to indicate a chronic state and poor prognosis for recovery (66). Other ocular motor signs include bilateral abducens nerve palsy followed by conjugate gaze palsy with horizontal gaze affected more than vertical. Complete ophthalmoplegia is an uncommon presentation of Wernicke encephalopathy. Vision loss is an uncommon symptom of the disease that might be the result of optic neuropathy with disc edema and retinal hemorrhages. Most ophthalmologic findings in Wernicke encephalopathy are reversible and improve dramatically with thiamine replacement treatment.
Hyperkinetic movement disorders in diabetes. Chorea, athetosis, ballism, or their combination are uncommon but often disabling conditions in patients with poorly controlled diabetes and can present as acute, chronic, or paroxysmal movement disorders (89). It has been suggested that the presence and degree of diabetic retinopathy can be an indirect marker of striatopallidal microangiopathy in patients with diabetes because both the retina and striatum/globus pallidus pars externa lack collateral blood circulation. Therefore, patients with a more advanced diabetic retinopathy have a higher risk of hyperkinetic movement disorders of diabetic striatopathy and a poorer prognosis for recovery (89).
Ophthalmologic signs of other movement disorders include the following:
|
• Kayser-Fleischer ring and sunflower cataract are unique ophthalmologic features of Wilson disease. | |
|
• Opsoclonus-myoclonus is an immune-mediated syndrome that is usually indicative of a paraneoplastic or parainfectious process. | |
|
• Convergence spasm can be seen in more than two-thirds of patients with psychogenic movement disorders, but it can occur in healthy individuals as well as in organic neurologic and ophthalmologic disorders. |
Wilson disease. The best-known ophthalmologic feature of Wilson disease is the Kayser-Fleischer ring, which is a clinically asymptomatic brown or green deposition of copper in the peripheral Descemet membrane around the iris, best visualized with a slit lamp. Sunflower cataract is another ocular sign of Wilson disease associated with copper deposition in the lens capsule, but it usually does not affect vision (134). Saccades, smooth pursuit, and range of ocular motility can also be affected, although these findings are not specific for Wilson disease (86).
Neurodegeneration with brain iron accumulation and neuroacanthocytosis. Neurodegeneration with brain iron accumulation disorders and neuroacanthocytosis often have prominent ophthalmologic features, including abnormal eye motility, such as impaired saccades and smooth pursuit; convergence insufficiency; gaze palsy; and apraxia of gaze (35; 121). Patients with neurodegeneration with brain iron accumulation can also present with visual dysfunction (retinitis pigmentosa and optic nerve atrophy resulting in diminished vision) and pupillary abnormality (eg, Adie pupils) (38).
Psychogenic movement disorders. Ocular symptoms, including complaints of blindness, double vision that often persists with monocular occlusion, psychogenic blepharospasm and hemifacial spasm, opsoclonus, and oculogyric movements, are frequently seen in psychogenic disorders (15). Convergence spasm was reported in 69% of patients with psychogenic movement disorders (42). This ocular sign is characterized by transient ocular convergence, miosis, and accommodation associated with dysconjugate gaze that mimics abducens palsy.
It is important to remember that convergence spasm can occur in healthy individuals as well as in organic neurologic and ophthalmologic disorders, such as strabismus, metabolic encephalopathy, encephalitis, genetic disorders of dopamine metabolism, multiple sclerosis, and brainstem ischemia; therefore, interpretation of this neuro-ophthalmologic finding should be conducted in the appropriate clinical context.
Whipple disease. Whipple disease is an infectious disorder caused by Tropheryma whipplei with multisystem involvement including prominent neuro-psychiatric presentation. Oculomasticatory myorhythmia is one of the most distinguishing features of Whipple disease and is characterized by pendular vergence oscillations of the eyes and concurrent contractions of masticatory muscles (122; 13). Other ocular symptoms of Whipple disease include retinitis, uveitis, vitreitis, papilledema, optic nerve atrophy, and nystagmus.
Opsoclonus-myoclonus syndrome. Opsoclonus-myoclonus syndrome (or dancing eyes-dancing feet syndrome) is an immune-mediated syndrome characterized by acute to subacute onset of neurologic and ocular symptoms including ataxia, abnormal eye movements (such as bizarre, non-rhythmic, involuntary horizontal and vertical eye movements/opsoclonus), myoclonic jerks, and behavioral changes (14). Parainfectious opsoclonus-myoclonus syndrome is usually associated with West Nile virus, cytomegalovirus, Epstein-Barr virus, HIV and Herpes viruses, and some bacterial infections. Paraneoplastic opsoclonus-myoclonus can manifest in children with neuroblastoma or in adults with squamous cell carcinoma or adenocarcinoma (10). Some of these disorders are associated with loss of peripheral vestibular function resulting in nystagmus and oscillopsia (illusion that the environment is moving), particularly during walking (125). Early diagnosis and treatment of the primary diseases is of paramount importance in the management of movement disorders of infectious or autoimmune etiology.
Oculopalatal tremor is a rare condition resulting from any interruption of a brainstem circuitry within the Guillain-Mollaret triangle formed by the contralateral dentate nucleus, ipsilateral red nucleus, and inferior olivary nucleus (21; 13). The disorder manifests as a combination of pendular nystagmus synchronous with rhythmical, 1 to 3 Hz, contractions of the soft palate and pharynx. Although palatal or pharyngeal tremor (also referred to as “palatal myoclonus”) is almost always asymptomatic, oscillopsia (visual illusion of to-and-fro movement of the environment) is usually disturbing to the patients.
Treatment with gabapentin or memantine might be effective in oculopalatal tremor (21).
Table 1. Neuro-Ophthalmologic Features in Movement Disorders
|
Disorders |
Ophthalmological findings |
|
Parkinson disease |
Visual function: impaired color discrimination and contrast sensitivity, decreased visual acuity, visuospatial deficit. |
|
Eyelid movements: blepharospasm, apraxia of eyelid opening, reduced blink rate, glabellar reflex. | |
|
Eye motility: hypometric saccades, impaired smooth pursuit (reduced peak velocity, progressive decline with repetitive movements, catch-up saccades), convergence insufficiency, upgaze limitation, impaired antisaccades and remembered saccades, square-wave jerks, impaired ocular fixation. | |
|
Visual hallucinations and illusions (sensation of presence or sideways passage, formed visual hallucinations). | |
|
Other sensory complaints: dry eyes, diplopia. | |
|
Progressive supranuclear palsy |
Eyelid movements: lid retraction, blepharospasm, apraxia of eyelid opening, reduced blink rate, impaired blink reflexes. |
|
Eye motility: decreased saccade velocity, abnormal vertical saccades more than horizontal, impaired antisaccades, vertical supranuclear gaze palsy, impaired smooth pursuit with catch-up saccades, square wave jerks, convergence insufficiency, persistent ocular fixation, difficulty suppressing vestibulo-ocular reflexes. | |
|
Other findings: constriction of pupils in the dark; “round the houses” sign. | |
|
Multiple system atrophy |
Eye motility: spontaneous or gaze-evoke nystagmus, square-wave jerks, slow and hypometric saccades, reduced vestibulo-ocular reflex suppression, reduced vertical gaze, impaired smooth pursuit. |
|
Corticobasal degeneration |
Eye motility: Impaired convergence, increased horizontal saccade latency with preserved saccade velocity, impairment of upward gaze or vertical saccades. |
|
Dementia with Lewy bodies |
Visual hallucinations. |
|
Eye motility: supranuclear vertical gaze palsy, impaired latency, velocity and accuracy of saccades. | |
|
Wilson disease |
Eye motility: slow saccades, rare ophthalmoparesis, impaired smooth pursuit with saccadic intrusion. |
|
Ocular: Kayser-Fleischer ring in Descemet membrane, sunflower cataracts. | |
|
Huntington disease |
Eye motility: difficulty initiating saccades, difficulty suppressing reflexive saccades, slowing of vertical and horizontal saccades, impaired smooth pursuit, preserved vestibulo-ocular reflex. |
|
Eyelid movements: increased blink rate, blepharospasm, apraxia of eyelid opening and closure. | |
|
Blepharospasm |
Sensory complaints: dry eye, photophobia, sensation of foreign object in the eye. |
|
Eyelid movements: blepharospasm, apraxia of eyelid opening. | |
|
Other dystonia |
Hemifacial spasm: usually unilateral eyelid spasm. |
|
Oculogyric crisis: paroxysmal conjugate eye deviation up or to one side. | |
|
Tourette syndrome |
Eyelid movements: increased blink rate, blepharospasm. |
|
Eye motility: oculogyric tics, increased errors on antisaccade tasks. | |
|
Ataxia syndromes |
Eye motility: gaze-evoked and spontaneous nystagmus, rebound nystagmus, impaired fixation, square-wave jerks, slow saccades, hypermetric or hypometric saccades, impaired vestibulo-ocular reflex gain, impaired smooth pursuit with saccadic intrusion, ophthalmoplegia (SCA7), apraxia of eye movements with difficulty initiating gaze. |
|
Eyelid movements: periorbital myokymia (EA-1). | |
|
Visual function: blindness due to progressive macular dystrophy (SCA7). | |
|
Other ocular findings: conjunctival telangiectasias, oculomotor apraxia (ataxia telangiectasia). | |
|
Neurodegeneration with brain iron accumulation and neuroacanthocytosis |
Eye motility: impaired saccades, abnormal smooth pursuit, limited upgaze, apraxia of gaze, supranuclear gaze palsy, convergence insufficiency, square-wave jerks. |
|
Eyelid movements: blepharospasm. | |
|
Visual function: optic atrophy, retinitis pigmentosa (neurodegeneration with brain iron accumulation). | |
|
Other findings: Adie pupils (neurodegeneration with brain iron accumulation). | |
|
Psychogenic movement disorders |
Visual function: monocular or binocular vision loss. |
|
Eyelid movements: blepharospasm, excessive blinking. | |
|
Eye motility: convergence spasm, oculogyric movements. | |
|
Other complaints: diplopia. | |
|
Other movement disorders with neuro-ophthalmologic signs |
Whipple disease: oculomasticatory myorhythmia, retinitis, uveitis, vitreitis, papilledema, optic atrophy, nystagmus. |
|
Opsoclonus-myoclonus syndrome: ocular opsoclonus. Oculopalatal tremor: pendular nystagmus, oscillopsia |
Media
References
- 01
- Acera A, Gómez-Esteban JC, Murueta-Goyena A, et al. Potential tear biomarkers for the diagnosis of Parkinson's Disease - a pilot study. Proteomes 2022;10(1):4. PMID 35076620
- 02
- Almer Z, Klein KS, Marsh L, Gerstenhaber M, Repka MX. Ocular motor and sensory function in Parkinson’s disease. Ophthalmology 2012;119:178-82. PMID 21959370
- 03
- Amini E, Moghaddasi M, Habibi SAH, et al. Huntington's disease and neurovascular structure of retina. Neurol Sci 2022;43(10):5933-41. PMID 35771295
- 04
- Anagnostou E, Karavasilis E, Potiri I, et al. A cortical substrate for square-wave jerks in progressive supranuclear palsy. J Clin Neurol 2020;16(1):37-45. PMID 31942756
- 05
- Anderson T, Luxon L, Quinn N, Daniel S, Marsden CD, Bronstein A. Oculomotor function in multiple system atrophy: clinical and laboratory features in 30 patients. Mov Disord 2008;23:977-84. PMID 18383533
- 06
- Antoniades CA, Spering M. Eye movements in Parkinson's disease: from neurophysiological mechanisms to diagnostic tools. Trends Neurosci 2024;47(1):71-83. PMID 38042680
- 07
- Antoniades CA, Xu Z, Mason SL, Carpenter RH, Barker RA. Huntington’s disease: changes in saccades and hand-tapping over 3 years. J Neurol 2010;257:1890-8. PMID 20585954
- 08
- Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson’s disease. Brain 2009;132:1128-45. PMID 19336464
- 09
- Archibald NK, Hutton SB, Clarke MP, Mosimann UP, Burn DJ. Visual exploration in Parkinson's disease and Parkinson's disease dementia. Brain 2013;136(Pt3):739-50. PMID 23436502
- 10
- Armangue T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol 2016;73(4):417-24. PMID 26856612
- 11
- Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. Clin Exp Optom 2011;94:150-60. PMID 20629667
- 12
- Armstrong RA. Visual dysfunction in Parkinson's disease. Int Rev Neurobiol 2017;134:921-46. PMID 28805589
- 13
- Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: phenomenology, etiology, and treatment. Mov Disord 2015;30(2):171-9. PMID 25487777
- 14
- Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord 2012;27:935-46. PMID 22555904
- 15
- Baizabal-Carvallo JF, Jankovic J. Psychogenic ophthalmologic movement disorders. J Neuropsychiatry Clin Neurosci 2016;28(3):195-8. PMID 26792096
- 16
- Beh SC, Frohman TC, Frohman EM. Neuro-ophthalmologic manifestations of cerebellar disease. Neurol Clin 2014;32(4):1009-80. PMID 25439294
- 17
- Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson’s disease. Neurology 2004;62:177-80. PMID 14745050
- 18
- Bodis-Wollner I. Foveal vision is impaired in Parkinson’s disease. Parkinsonism Relat Disord 2013;19:1-14. PMID 22998939
- 19
- Bodis-Wollner I, Miri S, Glazman S. Venturing into the no-man's land of the retina in Parkinson's disease. Mov Disord 2014;29(1):15-22. PMID 24339212
- 20
- Borm CDJM, Visser F, Werkmann M, et al. Seeing ophthalmologic problems in Parkinson disease: results of a visual impairment questionnaire. Neurology 2020;94(14):e1539-47. PMID 32161030
- 21
- Borruat FX. Oculopalatal tremor: current concepts and new observations. Curr Opin Neurol 2013;26:67-73. PMID 23254554
- 22
- Briand KA, Strallow D, Hening W, Poizner H, Sereno AB. Control of voluntary and reflexive saccades in Parkinson’s disease. Exp Brain Res 1999;129:38-48. PMID 10550501
- 23
- Brodsky H, Dat Vuong K, Thomas M, Jankovic J. Glabellar and palmomental reflexes in parkinsonian disorders. Neurology 2004;63(6):1096-8. PMID 15452308
- 24
- Buttner T, Kuhn W, Patzold T, Przuntek H. L-Dopa improves colour vision in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 1994;7:13-9. PMID 8579766
- 25
- Camacho-Ordonez A, Cervantes-Arriaga A, Rodríguez-Violante M, et al. Is there any correlation between alpha-synuclein levels in tears and retinal layer thickness in Parkinson's disease? Eur J Ophthalmol 2024;34(1):252-9. PMID 37151018
- 26
- Chen Y, Wang H, Wang B, et al. Retinal thinning as a marker of disease severity in progressive supranuclear palsy. J Mov Disord 2024;17(1):55-63. PMID 37748923
- 27
- Chorostecki J, Seraji-Bozorgzad N, Shah A, et al. Characterization of retinal architecture in Parkinson’s disease. J Neurol Sci 2015;355(1-2):44-8. PMID 26071887
- 28
- Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. Progressive supranuclear palsy: Neuropathological based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry 1995;58:167-73. PMID 7876846
- 29
- Coppen EM, Jacobs M, van den Berg-Huysmans AA, van der Grond J, Roos RAC. Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease. Parkinsonism Relat Disord 2018;46:56-61. PMID 29128164
- 30
- Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial. Lancet 2014;383(9916):533-40. PMID 24183563
- 31
- Devos D, Tir M, Maurage CA, et al. ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies. Neurology 2005;65:1107-10. PMID 16217068
- 32
- Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol 2009;5:331-42. PMID 19498436
- 33
- Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol 2002;59:1249-52. PMID 12164720
- 34
- Di Staso F, Ciancaglini M, Abdolrahimzadeh S, D'Apolito F, Scuderi G. Optical coherence tomography of choroid in common neurological diseases. In Vivo 2019;33(5):1403-9. PMID 31471385
- 35
- Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012;46(1):1-18. PMID 22266337
- 36
- Dusek P, Kopal A, Brichova M, et al. Is retina affected in Huntington's disease? Is optical coherence tomography a good biomarker? PLoS One 2023;18(2):e0282175. PMID 36827300
- 37
- Duval C. Ocular tremor in Parkinson's disease: the debate is not over. Mov Disord 2013;28(6):713-4. PMID 23674505
- 38
- Egan RA, Weleber RG, Hogarth P, et al. Neuro-ophthalmologic and electrophysiologic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden- Spatz syndrome). Am J Ophthalmol 2005;140:267-74. PMID 16023068
- 39
- Eraslan M, Cerman E, Yildiz Balci S, et al. The choroid and lamina cribrosa is affected in patients with Parkinson's disease: enhanced depth imaging optical coherence tomography study. Acta Ophthalmol 2016;94(1):e68-75. PMID 26268377
- 40
- Fabbrini G, Merello M, Evans AH, Lees AJ, Holton J, Williams DR. Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: clinicopathological case. Mov Disord 2011;26:424-9. PMID 21462257
- 41
- Farber RH, Swerdlow NR, Clementz BA. Saccadic performance characteristics and the behavioral neurology of Tourette’s syndrome. J Neurol Neurosurg Psychiatry 1999;66:305-12. PMID 10084528
- 42
- Fekete R, Baizabal-Carvallo JF, Ha AD, Davidson A, Jankovic J. Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry 2012;83:202-4. PMID 21949106
- 43
- Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-45. PMID 10734005
- 44
- FitzGerald P, Jankovic J. Tardive oculogyric crises. Neurology 1989;39:1434-7. PMID 2573005
- 45
- French DD, Margo CE. Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration. Cornea 2007;26(9):1087-9. PMID 17893540
- 46
- Friedman DI, Jankovic J, McCrary JA 3rd. Neuro-ophthalmic findings in progressive supranuclear palsy. J Clin Neuroophthalmol 1992;12:104-9. PMID 1629370
- 47
- Garbutt S, Riley DE, Kumar AN, Han Y, Harwood MR, Leigh RJ. Abnormalities of optokinetic nystagmus in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004;75:1386-94. PMID 15377682
- 48
- Garcia MD, Pulido JS, Coon EA, Chen JJ. Ocular features of multiple system atrophy. J Clin Neurosci 2018;47:234-9. PMID 29066238
- 49
- Gironell A, Kulisevsky J, Roig C, Pascual-Sedano B, Rodriguez-Fornells A, Otermin P. Diagnostic potential of acoustic startle reflex, acoustic blink reflex and electrooculography in progressive supranuclear palsy: a prospective study. Mov Disord 2003;18:1273-9. PMID 14639667
- 50
- Gitchel GT, Wetzel PA, Baron MS. Pervasive ocular tremor in patients with Parkinson disease. Arch Neurol 2012;69:1011-7. PMID 22490323
- 51
- Gitchel GT, Wetzel PA, Qutubuddin A, Baron MS. Experimental support that ocular tremor in Parkinson’s disease does not originate from head movement. Parkinsonism Relat Disord 2014;20(7):743-7. PMID 24767602
- 52
- Gorges M, Maier MN, Rosskopf J, et al. Regional microstructural damage and patterns of eye movement impairment: a DTI and video-oculography study in neurodegenerative parkinsonian syndromes. J Neurol 2017;264(9):1919-28. PMID 28762086
- 53
- Grandas F, Esteban A. Eyelid motor abnormalities in progressive supranuclear palsy. J Neurol Transm Suppl 1994;42:33-41. PMID 7964695
- 54
- Habibi M, Oertel WH, White BJ, et al. Eye tracking identifies biomarkers in α-synucleinopathies versus progressive supranuclear palsy. J Neurol 2022;269(9):4920-38. PMID 35501501
- 55
- Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Opththalmol 2009;127:737-41. PMID 19506190
- 56
- Hallett M, Evinger C, Jankovic J, Stacy M; BEBRF International Workshop. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 2008;71:1275-82. PMID 18852443
- 57
- Halliday GM, Hardman CD, Cordato NJ, et al. A role for the substantia nigra pars reticulata in the gaze palsy of progressive supranuclear palsy. Brain 2000;123:724-32. PMID 10734004
- 58
- Hamedani AG, Willis AW. Self-reported visual dysfunction in Parkinson disease: the survey of health, ageing and retirement in Europe. Eur J Neurol 2020;27(3):484-9. PMID 31571317
- 59
- Hamm-Alvarez SF, Janga SR, Edman MC, et al. Levels of oligomeric α-Synuclein in reflex tears distinguish Parkinson's disease patients from healthy controls. Biomark Med 2019;13(17):1447-57. PMID 31552762
- 60
- Hardwick A, Rucker JC, Cohen ML, et al. Evolution of oculomotor and clinical findings in autopsy-proven Richardson syndrome. Neurology 2009;73:2122-4. PMID 20018641
- 61
- Harnois C, DiPaolo T. Decreased dopamine in the retina of patients with Parkinson disease. Invest Ophthalmol Vis Sci 1990;31:2473-5. PMID 2243012
- 62
- Hepp DH, Foncke EMJ, Olde Dubbelink KTE, van de Berg WDJ, Berendse HW, Schooheim MM. Loss of functional connectivity in patients with Parkinson disease and visual hallucinations. Radiology 2017;285(3):896-903. PMID 28952907
- 63
- Hicks SL, Robert MP, Golding CV, Tabrizi SJ, Kennard C. Oculomotor deficits indicate the progression of Huntington’s disease. Prog Brain Res 2008;171:555-8. PMID 18718352
- 64
- Hutton JT, Morris JL. Vision in Parkinson’s disease. Adv Neurol 2001;86:279-88. PMID 11553987
- 65
- Hutton JT, Morris JL, Elias JW. Levodopa improves spatial contrast sensitivity in Parkinson’s disease. Arch Neurol 1993;50:721-4. PMID 8323475
- 66
- Isen DR, Kline LB. Neuro-ophthalmic manifestations of Wernicke encephalopathy. Eye Brain 2020;12:49-60. PMID 32636690
- 67
- Ishino H, Higashi H, Kuroda S, Yabuki S, Hayahara T. Motor nuclear involvement in progressive supranuclear palsy. J Neurol Sci 1974;22:235-44. PMID 4829195
- 68
- Iwaki H, Sogo H, Morita H, et al. Using spontaneous eye-blink rates to predict the motor status of patients with Parkinson's disease. Intern Med 2019;58(10):1417-21. PMID 31092772
- 69
- Jankovic J. Apraxia of lid opening. Mov Disord 1995;10:686-7. PMID 8552131
- 70
- Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry 1996;60:704. PMID 8648354
- 71
- Jankovic J. Peripherally induced movement disorders. Neurol Clin 2009;27:821-32. PMID 19555833
- 72
- Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial. Mov Disord 2011;26:1521-8. PMID 21520284
- 73
- Jankovic J, Kurlan R. Tourette Syndrome: Evolving concepts. Mov Disord 2011;26:1149-56. PMID 21484868
- 74
- Jankovic J, Stone L. Dystonic tics in patients with Tourette’s syndrome. Mov Disord 1991;6:248-52. PMID 1922130
- 75
- Jones RD, Donaldson IM, Timmings PL. Impairment of high-contrast visual acuity in Parkinson’s disease. Mov Disord 1992;7:232-8. PMID 1620141
- 76
- Kagohashi M, Okuma Y, Fujishima K, Kitada T, Mizuno Y. Blepharospasm associated with multiple system atrophy: a case report and review of the literature. Parkinsonism Relat Disord 2004;10:169-71. PMID 15036172
- 77
- Kapoula Z, Yang Q, Vernet M, Dieudonne B, Greffard S, Verny M. Spread deficits in initiation, speed and accuracy and vertical automatic saccades in dementia with Lewy bodies. Front Neurol 2010;1:138. PMID 21212841
- 78
- Kaski D, Saifee TA, Buckwell D, Bronstein AM. Ocular tremor in Parkinson’s disease is due to head oscillation. Mov Disord 2013;28(4):534-7. PMID 23389811
- 79
- Kennard C, Lueck CJ. Oculomotor abnormalities in diseases of the basal ganglia. Rev Neurol 1989;145:587-95. PMID 2530611
- 80
- Krol-Grzymala A, Sienkiewicz-Szłapka E, Fiedorowicz E, Rozmus D, Cieślińska A, Grzybowski A. Tear biomarkers in Alzheimer's and Parkinson's diseases, and multiple sclerosis: implications for diagnosis (systematic review). Int J Mol Sci 2022;23(17):10123. PMID 36077520
- 81
- Kurian MA, Gissen P, Smith M, Heales S Jr, Clayton PT. The monoamine neurotransmitter disorders: an expending range of neurological syndromes. Lancet Neurol 2011;10:721-33. PMID 21777827
- 82
- La Morgia C, Barboni P, Rizzo G, et al. Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern. Eur J Neurol 2013;20:198-201. PMID 22436028
- 83
- Lee JY, Kim JM, Ahn J, Kim HJ, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson's Disease. Mov Disord 2014;29(1):61-7. PMID 23775932
- 84
- Lekwuwa GU, Barnes GR, Collins CJS, Limousin P. Progressive bradykinesia and hypokinesia of ocular pursuit in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;66:746-53. PMID 10329748
- 85
- Lepore FE, Duvoisin RC. “Apraxia” of eyelid opening an involuntary levator inhibition. Neurology 1985;35:423-7. PMID 3974904
- 86
- Lesniak M, Czlonkowska A, Seniow J. Abnormal antisaccades and smooth pursuit eye movements in patients with Wilson’s disease. Mov Disord 2008;23:2067-73. PMID 18759342
- 87
- Leyland LA, Bremner FD, Mahmood R, et al. Visual tests predict dementia risk in Parkinson disease. Neurol Clin Pract 2020;10(1):29-39. PMID 32190418
- 88
- Lispi ML, Vigevano F. Benign paroxysmal tonic upgaze of childhood with ataxia. Epileptic Disord 2001;3:203-6. PMID 11844715
- 89
- Lizarraga KJ, Chunga N, Yannuzzi NA, Flynn HW Jr, Singer C, Lang AE. The retina as a window to the basal ganglia: systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. Parkinsonism Relat Disord 2020;80:194-8. PMID 33069611
- 90
- Lu Z, Buchanan T, Kennard C, FitzGerald JJ, Antoniades CA. The effect of levodopa on saccades - Oxford Quantification in Parkinsonism study. Parkinsonism Relat Disord 2019;68:49-56. PMID 31621619
- 91
- Ma X, Li S, Zheng B, et al. Retinal structure abnormalities in Parkinson's disease and atypical parkinsonism. Biomolecules 2023;13(2):218. PMID 36830588
- 92
- MacAskill MR, Anderson TJ. Eye movements in neurodegenerative diseases. Curr Opin Neurol 2016;29(1):61-8. PMID 26641817
- 93
- Mancera N, Wadia HP. Corneal edema associated with systemic dopaminergic agents. Cornea 2019;38(8):1040-2. PMID 30950895
- 94
- Merims D, Shabtai H, Korczyn AD, Peterz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm 2004;111:1447-53. PMID 15480845
- 95
- Misra SL, Kersten HM, Roxburgh RH, Danesh-Meyer HV, McGhee CN. Corneal nerve microstructure in Parkinson’s disease. J Clin Neurosci 2017;39:53-8. PMID 28268149
- 96
- Muller T, Woitalla D, Peters S, Kohla K, Przuntek H. Progress of visual dysfunction in Parkinson’s disease. Acta Neurol Scand 2002;105:256-60. PMID 11939937
- 97
- Murueta-Goyena A, Romero-Bascones D, Teijeira-Portas S, et al. Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson's disease. NPJ Parkinsons Dis 2024;10(1):26. PMID 38263165
- 98
- Nagino K, Sung J, Oyama G, et al. Prevalence and characteristics of dry eye disease in Parkinson's disease: a systematic review and meta-analysis. Sci Rep 2022;12(1):18348. PMID 36319814
- 99
- Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson’s disease. Surg Radiol Anat 1988;10:137-44. PMID 3135618
- 100
- Oh YS, Kim JS, Chung SW, et al. Color vision in Parkinson’s disease and essential tremor. Eur J Neurol 2011;18:577-83. PMID 21435106
- 101
- Park JY, Joo K, Woo SJ. Ophthalmic manifestations and genetics of the polyglutamine autosomal dominant spinocerebellar ataxias: a review. Front Neurosci 2020;14:892. PMID 32973440
- 102
- Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014;13(1):100-12. PMID 24331796
- 103
- Patel SS, Jankovic J, Hood AJ, Jeter CB, Sereno AB. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci 2012;313:35-41. PMID 22018763
- 104
- Peckham EL, Lopez G, Shamim EA, et al. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol 2011;18:382-6. PMID 20649903
- 105
- Phokaewvarangkul O, Bhidayasiri R. How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. Transl Neurodegener 2019;8:20. PMID 31333840
- 106
- Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehab 1997;78:525-9. PMID 9161374
- 107
- Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson’s disease. J Neurol Sci 2000;172:7-11. PMID 10620653
- 108
- Pretegiani E, Optican LM. Eye movements in Parkinson's disease and inherited parkinsonian syndromes. Front Neurol 2017;8:592. PMID 29170650
- 109
- Quinn N. The "round the houses" sign in progressive supranuclear palsy. Ann Neurol 1996;40(6):951. PMID 9007109
- 110
- Rana AQ, Kabir A, Dogu O, Patel A, Khondker S. Prevalence of blepharospasm and apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential tremor. Eur Neurol 2012;68(5):318-21. PMID 23075668
- 111
- Rascol O, Sabatini U, Fabre N, et al. Abnormal vestibuloocular cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson’s disease. Mov Disord 1995;10:163-70. PMID 7753058
- 112
- Rezende Filho FM, Jurkute N, de Andrade JBC, et al. Characterization of retinal architecture in spinocerebellar ataxia type 3 and correlation with disease severity. Mov Disord 2022;37(4):758-66. PMID 34936137
- 113
- Rivaud-Péchoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000;54:1029-32. PMID 10720270
- 114
- Riise R, Ygge J, Lindman C, et al. Ocular findings in Norwegian patients with ataxia-telangiectasia: a 5 year prospective cohort study. Acta Ophthalmol Scand 2007;85:557-62. PMID 17376192
- 115
- Roda M, Ciavarella C, Giannaccare G, Versura P. Biomarkers in tears and ocular surface: a window for neurodegenerative diseases. Eye Contact Lens 2020;46 Suppl 2:S129-34. PMID 31658175
- 116
- Romano S, Colosimo C. Procerus sign in progressive supranuclear palsy. Neurology 2001;57:1928. PMID 11723296
- 117
- Rupp J, Dzemidzic M, Blekher T, et al. Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in premanifest and manifest Huntington disease. J Neurol 2012;259:267-76. PMID 21850389
- 118
- Sari ES, Koc R, Yazici A, Sahin G, Ermis SS. Ganglion cell-inner plexiform layer thickness in patients with Parkinson disease and association with disease severity and duration. J Neuroophthalmol 2015;35(2):117-21. PMID 25485861
- 119
- Satue M, Obis J, Alarcia R, et al. Retinal and choroidal changes in patients with Parkinson's disease detected by swept-source optical coherence tomography. Curr Eye Res 2018;43(1):109-15. PMID 29111842
- 120
- Schmidt C, Herting B, Prieur S, et al. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Mov Disord 2007;22:2123-6. PMID 17853484
- 121
- Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Current Neuropharmacol 2013;11(1):59-79. PMID 23814539
- 122
- Schwartz MA, Selhorst JB, Ochs AL, et al. Oculomasticatory myorhythmia: a unique movement disorder occurring in Whipple’s disease. Ann Neurol 1986;20:677-83. PMID 2434019
- 123
- Shaunak S, O’Sullivan EO, Blunt S, et al. Remembered saccades with variable delay in Parkinson’s disease. Mov Disord 1999;14:80-6. PMID 9918348
- 124
- Stamey W, Jankovic J. The other Babinski sign in hemifacial spasm. Neurology 2007;69:402-4. PMID 17646635
- 125
- Straube A, Bronstein A, Straumann D. Nystagmus and oscillopsia. Eur J Neurol 2012;19(1):6-14. PMID 21906211
- 126
- Ticku H, Fotedar N, Juncos J, Factor SA, Shaikh AG. Pseudonystagmus in progressive supranuclear palsy. J Neurol Sci 2022;434:120157. PMID 35131549
- 127
- Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology 2005;65:1907-13. PMID 16282276
- 128
- Vidailhet M, Rivaud S, Gouider-Khouja N, et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994;35:420-6. PMID 8154868
- 129
- Vijayakumar D, Wijemanne S, Jankovic J. Treatment of blepharospasm with apraclonidine. J Neurol Sci 2017;372:57-9. PMID 28017248
- 130
- Vilensky JA, Gilman S, McCall S. A historical analysis of the relationship between encephalitis lethargica and postencephalitic parkinsonism: a complex rather than a direct relationship. Mov Disord 2010;25:1116-23. PMID 20629120
- 131
- Visser F, Apostolov VI, Vlaar AMM, Twisk JWR, Weinstein HC, Berendse HW. Visual hallucinations in Parkinson's disease are associated with thinning of the inner retina. Sci Rep 2020;10(1):21110. PMID 33273513
- 132
- Waln O, Jankovic J. Paroxysmal movement disorders. Neurol Clin 2015;33(1):137-52. PMID 25432727
- 133
- Waln O, Jankovic J. Neuro-ophthalmology of movement disorders. Exp Rev Ophthal 2018;13(5):283-92.
- 134
- Walshe JM. The eye in Wilson disease. QJM 2011;104:451-3. PMID 20444834
- 135
- Whitwell JL, Avula R, Master A, et al. Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord 2011;17:599-605. PMID 21665514
- 136
- Wijemanne S, Jankovic J. Dopa-responsive dystonia--clinical and genetic heterogeneity. Nat Rev Neurol 2015;11(7):414-24. PMID 26100751
- 137
- Willard A, Lueck CJ. Ocular motor disorders. Curr Opin Neurol 2014;27(1):75-82. PMID 24300789
- 138
- Yaltho TC, Jankovic J. The many faces of hemifacial spasm: Differential diagnosis of unilateral facial spasms. Mov Disord 2011;26:1582-92. PMID 21469208
- 139
- Yoon WT, Chung EJ, Lee SH, Kim BJ, Lee WY. Clinical analysis of blepharospasm and apraxia of eyelid opening in patients with parkinsonism. J Clin Neurol 2005;1:159-65. PMID 20396463
- 140
- Zhang Y, Yang L, Gao Y, et al. Choroid and choriocapillaris changes in early-stage Parkinson's disease: a swept-source optical coherence tomography angiography-based cross-sectional study. Alzheimers Res Ther 2022;14(1):116. PMID 36008844
- 141
- Zhao Y, Dai WJ. Characteristics of change on retinal nerve fiber layer thickness in mild Parkinson’s disease. International Eye Science 2015;15(1):159-61.
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Olga Waln MD
Dr. Waln of Houston Methodist Neurological Institute has no relevant financial relationships to disclose.
See Profile
Editor
-
Robert Fekete MD
Dr. Fekete of New York Medical College received consultation fees from Acadia Pharmaceutical, Acorda, Adamas/Supernus Pharmaceuticals, Amneal/Impax, Kyowa Kirin, Lundbeck Inc., Neurocrine Inc., and Teva Pharmaceutical, Inc.
See Profile
Patient Profile
- Age range of presentation
-
- 1 month to 65+ years
- Sex preponderance
-
- No sex preponderance
- Heredity
-
- heredity may be a factor (see individual disorders)
- autosomal dominant
- autosomal recessive
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Agenesis of the cerebellum: Q04.3
- Alcoholic cerebellar degeneration: G31.2
- Alcohol-related ataxia: F10.2
- Ataxia telangiectasia: G11.3
- Blepharospasm (idiopathic cranial dystonia, Meige's syndrome): G24.5
- Brain ataxia: G31.88
- Combined vocal and multiple motor tic disorder [de la Tourette]: F95.2
- Congenital nonprogressive ataxia: G11.0
- Degenerative disease of nervous system, unspecified: G31.9
- Early-onset cerebellar ataxia: G11.1
- Extrapyramidal and movement disorder, unspecified: G25.9
- Gait ataxia: R26.0
- Hemifacial spasm: G51.8
- Hereditary ataxia, unspecified: G11.9
- Hereditary ataxia: G11
- Huntington disease: G10
- Idiopathic nonfamilial dystonia: G24.2
- Idiopathic orofacial dystonia: G24.4
- Late-onset cerebellar ataxia: G11.2
- Myoclonus: G25.3
- Neuropathy in association with hereditary ataxia: G60.2
- Ocular dystonia, nonfamilial: G24.230
- Other and unspecified lack of coordination: R27.8
- Other cranial dystonia, nonfamilial: G24.23
- Other hereditary ataxias: G11.8
- Other specified degenerative diseases of basal ganglia: G23.8
- Other specified degenerative diseases of basal ganglia: G23.8
- Other specified degenerative diseases of basal ganglia: G23.81+
- Other specified degenerative diseases of nervous system: G31.8
- Other specified extrapyramidal and movement disorders: G25.8
- Other specified neurotic disorders: F48.8
- Parkinson disease: G20
- Progressive ataxia: A52.1
- Progressive supranuclear palsy: G23.1
- Wernicke encephalopathy: E51.2
- Whipple disease: K90.8 + M14.8
- Wilson disease: E83.0
- ICD-11
-
- Ataxia due to alcoholic cerebellar degeneration: 8A03.30
- Ataxia due to mitochondrial mutations: 8A03.15
- Ataxic gait: MB44.0
- Congenital ataxia: 8A03.0
- DNA repair defects other than combined T-cell or B-cell immunodeficiencies: 4A01.31
- Dystonia: MB47.4
- Hemifacial spasm: 8B88.2
- Hereditary ataxia: 8A03.1
- Huntington disease: 8A01.10
- Hypoplasia or agenesis of cerebellar hemispheres: LA06.1
- Movement disorders of eyelid: 9A05
- Myoclonic disorders: 8A06
- Other specified acquired ataxia: 8A03.3Y
- Other specified disorders of the nervous system: 8E4Y
- Other specified hereditary ataxia: 8A03.1Y
- Other specified intestinal malabsorption: DA96.0Y
- Other specified movement disorders: 8A0Y
- Parkinson disease: 8A00.0
- Primary dystonia: 8A02.0
- Progressive supranuclear palsy: 8A00.10
- Secondary dystonia: 8A02.1
- Tourette syndrome: 8A05.00
- Wernicke encephalopathy: 5B5A.10
- Wilson disease: 5C64.00
- OMIM
-
- Parkinson disease: #168600
- Progressive supranuclear palsy 1: #601104
- Progressive supranuclear palsy 2: %609454
- Dementia, Lewy Body; DLB: #127750
- Huntington disease: #143100
- Facial spasm: 134300
- Gilles de la Tourette syndrome: #137580
- Modifier of Tourette syndrome: 309840
- Wilson disease: #277900
- Hallervorden-Spatz disease: #234200
- Ataxia-telangiectasia: #208900
- Episodic ataxia, type 1: #160120
- Episodic ataxia, type 2: #108500
- Spinocerebellar ataxia 1: #164400
- Spinocerebellar ataxia 2: #183090
- Spinocerebellar ataxia 3 (Machado-Joseph disease): #109150
- Spinocerebellar ataxia 6: #183086
- Spinocerebellar ataxia 7: #164500
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neurogenetic Disorders
Wilson disease
Oct. 23, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Giant cell arteritis
Sep. 25, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Ischemic optic neuropathy
Sep. 25, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Transient visual loss
Sep. 25, 2024
-
Neuro-Oncology
Vestibular schwannoma
Sep. 19, 2024
-
Neuro-Ophthalmology & Neuro-Otology
Ophthalmic electrophysiology
Sep. 12, 2024
-
General Neurology
Hyperventilation syndrome
Sep. 03, 2024
Related Article: